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Background. Preconditioning protects against both
liver and lung damage after hepatic ischemia-reperfu-
sion (I/R). Xanthine and xanthine oxidase (XOD) may
contribute to the development of hepatic I/R.
Objective. To evaluate whether preconditioning
could modulate the injurious effects of xanthine/XOD
on the liver and lung after hepatic I/R.
Methods. Hepatic I/R or preconditioning previous to
I/R was induced in rats. Xanthine and xanthine dehy-
drogenase/xanthine oxidase (XDH/XOD) in liver and
plasma were measured. Hepatic injury and inflamma-
tory response in the lung was evaluated.
Results. Preconditioning reduced xanthine accumu-
lation and conversion of XDH to XOD in liver during
sustained ischemia. This could reduce the generation
of reactive oxygen species (ROS) from XOD, and there-
fore, attenuate hepatic I/R injury. Inhibition of XOD
prevented postischemic ROS generation and hepatic
injury. Administration of xanthine and XOD to precon-
ditioned rats led to hepatic MDA and transaminase
levels similar to those found after hepatic I/R. Precon-
ditioning, resulting in low circulating levels of xan-
thine and XOD activity, reduced neutrophil accumu-
lation, oxidative stress, and microvascular disorders
seen in lung after hepatic I/R. Inhibition of XOD atten-
uated the inflammatory damage in lung after hepatic
I/R. Administration of xanthine and XOD abolished
the benefits of preconditioning on lung damage.
Conclusions. Preconditioning, by blocking the xan-
thine/XOD pathway for ROS generation, would confer
protection against the liver and lung injuries induced
by hepatic I/R.
Ischemia-reperfusion (I/R) is an unavoidable process in
liver transplantation, and protection of liver against injuries
resulting from ischemia-reperfusion (I/R) remains one of the
major nonimmunologic problems of liver transplantation (1,
2). One of the mechanisms thought to cause hepatic injury
during I/R is the formation of reactive oxygen species (ROS).
Potential sources of ROS are the activation of Kupffer cells
and neutrophils (3), the oxidation of heme proteins under the
acid conditions associated with ischemia (4), and xanthine/
xanthine oxidase (XOD) (5). During ischemia, xanthine de-
hydrogenase (XDH) is converted to the oxygen radical-pro-
ducing form, XOD. Concurrently, there is an accumulation of
the substrate for XOD, xanthine. Upon reoxygenation, XOD
reacts with molecular oxygen to produce ROS, which mediate
subsequent injurious events (6). It is well known that during
I/R processes, antioxidant systems such as glutathione
(GSH) and superoxide dismutase (SOD) could be depleted or
inactivated, respectively, leading to an increased vulnerabil-
ity of liver to ROS damage (7, 8).
On the other hand, the injurious effects of ROS are not
limited to the liver. There is evidence indicating that the
release of xanthine and XOD from the liver into the blood-
stream plays an essential role in the pathogenesis of systemic
complications of hepatic I/R, including neutrophil infiltration
and oxidant stress into the lung (5, 9, 10). Consequently, any
mechanism with the capability to act on the liver xanthine/
XOD system, either by reducing the conversion rate of XDH
to XOD or the amount of substrates available to XOD could
be considered useful to attenuate the injurious effects of ROS
seen in liver and lung as a consequence of hepatic I/R.
An inducible potent endogenous mechanism against I/R
injury has been termed ischemic preconditioning. This phe-
nomenon, commonly studied in the heart by Murry et al. in
1986 (11), has been also demonstrated in other organs, such
as brain (12), intestine (13), and liver (14). Despite intensive
investigations, however, the mechanisms responsible for the
protective effects of preconditioning remain unresolved. A
potential mechanism responsible for the protective effect of
preconditioning could be the induction of endogenous defense
systems against ROS. In the heart and intestine, several
studies have reported that ischemic preconditioning could
attenuate the ROS increase in tissues subsequently exposed
to prolonged I/R (15–18). These reduction in ROS levels have
been explained by an increase in the antioxidants pool (SOD
or GSH), which remove ROS (15–17), or by the effect of
preconditioning on ROS-generating systems such as neutro-
phils (15) or xanthine/XOD (18). However, there is controver-
sial data in the literature, because the results obtained by
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other authors in the heart seem to indicate that the effective-
ness of ischemic preconditioning could not be explained by an
increased myocardial resistance to ROS (19–21).
To our knowledge, the possibility that preconditioning
could modulate the injurious effects of ROS after hepatic I/R
has not been determined. Recently, we reported that isch-
emic preconditioning attenuated both the liver and lung in-
juries associated with hepatic I/R (22, 23). Our hypothesis
suggests that this process would be effected by modulating
those mechanisms involved in both local and systemic disor-
ders, including xanthine and XOD. The deleterious effects of
xanthine could not be exclusively limited to the ROS gener-
ation from XOD. Previous studies indicate that xanthine is
also an inhibitor of adenosine receptors (24). It is known that
the activation of adenosine receptors by ischemic precondi-
tioning or by pharmacological treatments may induce the
nitric oxide synthesis, thus reducing the hepatic I/R injury in
warm and cold ischemia conditions (25–27).
The present study evaluates (1) whether ischemic precon-
ditioning acting on the tandem xanthine/XOD, by decreasing
the amount of xanthine and/or the conversion of XDH to XOD
in liver, could protect against hepatic injury induced by I/R;
(2) the role of antioxidant system, SOD and GSH, in the
protection conferred by preconditioning on hepatic injury;
and (3) whether ischemic preconditioning could modulate the
levels of circulating xanthine and/or XOD, thus attenuating
the lung injury induced by hepatic I/R. Understanding the
mechanisms involved in ischemic preconditioning could help
to provide new surgical and pharmacological strategies to
protect against hepatic I/R injury.
MATERIAL AND METHODS
Surgical Procedure
The study was performed on male Wistar rats weighing between
250 and 300 g. Animals were anesthetized with urethane (10 mg/kg,
i.p.) and placed in a supine position on a heating pad to maintain
body temperature at 36–37°C. To induce hepatic ischemia, laparot-
omy was performed and the blood supply to the right lobe of the liver
was interrupted by placement of a bulldog clamp at the level of the
hepatic artery and portal vein. Reflow was initiated by removing the
clamp (14). This study was performed in concordance with the Eu-
ropean Union regulations (Directive 86/609 EEC) for animal
experiments.
Experimental Design
To evaluate the effect of preconditioning on ROS generating and
antioxidant systems in liver after hepatic ischemia, animals were
distributed into the following groups:
1. Control (C) (n6): animals subjected to anesthesia and
laparotomy.
2. Ischemia (I) (n6): animals subjected to 90 min of right-lobe
hepatic ischemia.
3. Preconditioning  ischemia (PCI) (n6): same as group 2 but
with preconditioning induced by 10 min of ischemia followed by 10
min of reperfusion before ischemia.
After the sustained ischemia, liver samples were obtained, imme-
diately frozen, and maintained at 80°C until analytical determina-
tions of SOD, GSH, xanthine, and XDH/XOD activity.
To evaluate the effect of preconditioning on the release of xanthine
and XOD from the liver into the bloodstream after restoration of
blood flow, animals subjected to the same procedures as in groups 2
and 3 were subjected to 15 min of reperfusion after 90 min of
ischemia. After 15 min of hepatic reperfusion, blood samples were
obtained from the cava vein and processed to determine xanthine
and XDH/XOD activity.
To study whether the effect of preconditioning on ROS generating
and/or antioxidant systems could modulate the postischemic ROS
generation and consequently the hepatic I/R injury associated with
this process, animals were distributed into the following groups:
4. Ischemia-reperfusion (I/R) (n6): animals subjected to 90 min of
right-lobe hepatic ischemia (as in group 2) followed by 90 min of
reperfusion.
5. PCI/R (n6): same as group 4 but with previous precondition-
ing induced by 10 min of ischemia and 10 min of reperfusion before
sustained ischemia.
6. I/Rallopurinol (n6): same as group 4 but with prior admin-
istration of an inhibitor of xanthine oxidase, allopurinol (100 mg/kg,
portal vein) 15 min before reperfusion (28).
7. PCI/RxanthineXOD (n6): same as group 5, but with a
continuous intravenous infusion of xanthine (5 mM; 0.033 ml/min)
and xanthine oxidase (0.2 U/L; 0.033 ml/min) (portal vein) for 30
min, 5 min before the start of reperfusion (29). The two drugs were
maintained in separate syringes and they reached a common cathe-
ter just before entering the bloodstream.
8. PCI/RallopurinolxanthineXOD (n6): same as group 5
but with a continuous intravenous infusion of xanthine (5 mM; 0.033
ml/min) and xanthine oxidase (0.2U/L; 0.033 ml/min) for 30 min, 5
min before the start of reperfusion and with prior administration of
allopurinol at dose of 100 mg/kg 15 min before reperfusion.
9. I/Rglutathione ester (I/RGSH) (n6): same as group 4 but
with administration of GSH ester (5 mmol/kg, portal vein) 5 min
before reperfusion (30).
At the end of 90 min of reperfusion, blood, liver, and lung samples
were obtained. Blood samples were collected to determine plasma
aminotransferases (aspartate aminotransferase [AST], alanine ami-
notransferase [ALT]). Liver samples were processed to determine
lipoperoxides (MDA), SOD, and GSH. Lung samples were processed
to determine MDA and myeloperoxidase (MPO) activity. Vascular
permeability analysis in lung and histological analysis in liver and
lung were performed.
The reperfusion time to evaluate the release of xanthine and XOD
from the liver into the bloodstream after restoration of blood flow
was as described by Weinbroum et al. (9). The dose and pretreatment
times of GSH ester administration has been reported to be effective
in evaluate the effects of GSH depletion on hepatic I/R injury. GSH
itself is not suitable because GSH is not taken up by cells in its intact
form, because it is degraded into its constituent amino acids before
entering the cells. The GSH ester is readily permeable to cells. Once
inside the cell cytosol the ester is hydrolyzed by an esterase to yield
GSH. The ester is most effective in increasing hepatic GSH levels
(30).
Control experiments were performed with the vehicles containing
the different drugs. Allopurinol, xanthine, XOD, and GSH ester were
supplied by Sigma Chemical Co. (St. Louis, MO).
Biochemical Determinations
Xanthine measurement. For the analysis of xanthine concentra-
tion in liver, tissues were homogenized in 3.6% perchloric acid. After
homogenization, tissues were allowed to extract for 30 min at 0.5°C.
For the analysis of xanthine in plasma, 500 l of blood was placed in
1.0 ml of 3.6% perchloric acid at 5°C for 30 min. After centrifugation,
the supernatants (corresponding to liver and plasma samples) were
neutralized with a potassium carbonate-potassium hydroxide solu-
tion to pH 6.5–7.0. The assay mixture consisted of Na2CO3 (0.05 M,
pH 10.2), EDTA (104 M); nitroblue tetrazolium (1.5104 M), and
XOD (100 U/L). The reduction of nitroblue tetrazolium to formazan
was recorded at 560 nm (31).
XDH and XOD activity. Liver tissues were homogenized in 100
mM Tris, containing 10 mM EDTA, 1 mM phenylmethylsulfonyl
fluoride, and 1 mM dithiothreitol. The homogenate was then spun
down at 15,000 g at 4°C and the pellet discarded. The supernatant
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was chromatographed on Sephadex G-25 80 column in the same
buffer at 4°C (32). To analyze XDH and XOD in plasma samples, a
total of 500 l of plasma supernatant was passed through a Seph-
adex G-25 80 column. The resultant eluates (corresponding to liver
and plasma samples) were used for measurement of XDH and XOD
activity. Activities were measured spectrophotometrically on the ba-
sis of uric acid formation at 292 nm in the presence or absence of 0.60
nM NAD, respectively. Xanthine (60 mM) was used as substrate.
The kinetics of the reaction was recorded for 10 min at 20°C.
Glutathione measurement. For the analysis of GSH, liver samples
were homogenized in 1.1% KCl. Proteins were precipitated with 1 N
perchloric acid. After centrifugation, samples were neutralized with
10% K2CO3 (18). The amount of GSH was measured using glutathi-
one transferase and 1-chloro-2,4-dinitrobenzene (33). Fifty microli-
ters of the previous treated sample was mixed with 225 l of 0.1 M
potassium phosphate buffer, pH 7.0, and 10 l of 10 mM 1-chloro-
2,4-dinitrobenzene in ethanol. The reaction was started with 5 l of
glutathione transferase solution (12 U/L) and monitored at 340–400
nm reaching the end-point 5 min after enzyme addition.
Superoxide dismutase assay. For SOD determination, liver sam-
ples were homogenized in 100 mM Tris (hydroxymethyl) aminometh-
ane (Tris)-HCl buffer with 0.2 mM phenylmethylsulfonyl fluoride
and 0.5 mM dithiothreitol (pH 8.1). SOD activity was assayed by
determining the ability of the enzyme to inhibit the superoxide
anion-mediated reduction of nitroblue tetrazolium (25 M) to
formazan, according to the method of Sun et al. (34). The later was
determined spectrophotometrically at 560 nm. The superoxide anion
required for this reaction is generated by xanthine (0.1 mM) and
xanthine oxidase (200 U/L).
Lipid peroxidation assay. Lipid peroxidation has been used as an
indirect measurement of oxidative damage induced by ROS (35).
Lipid peroxidation in liver and lung samples was determined by the
thiobarbiturate (TBA) reaction measuring the formation of malondi-
aldehyde (MDA). For this purpose, 2 ml of trichloroacetic acid (20%)
was added to 2 ml of homogenate. After mixing and centrifuging, 1
ml of TBA-water solution (0.67%) was added to the supernatant and
boiled for 60 min. After cooling, optical density at 530 nm was
assayed (23, 36).
Hepatic injury. Evaluation of hepatic injury was performed by
enzymatic determinations of AST and ALT plasma levels using a
commercial kit from Boehringer Mannheim (Munich, Germany).
Myeloperoxidase assay. Myeloperoxidase (MPO) has been used
as a marker of pulmonary neutrophil infiltration and activation
(37). MPO activity was measured photometrically employing
3,3',5,5'-tetramethylbenzidine as a substrate (38). Lung samples
were macerated with 0.5% hexadecyltrimethylammonium bro-
mide in 50 mM phosphate buffer pH 6. Homogenates were then
disrupted by sonication for 30 sec and subsequently snap frozen in
dry ice and thawed three times before a final 30 sec sonication.
Samples were incubated at 60°C for 2 hr and then spun down at
4000g for 12 min. Supernatants were collected for MPO assay.
Enzyme activity was assessed photometrically. The assay mixture
consisted in 20 l supernatant, 10 l tetramethylbenzidine (final
concentration 1.6 mM) dissolved in DMSO, and 70 l H2O2 (final
concentration 3.0 mM) diluted in 80 mM phosphate buffer pH 5.4.
An enzyme unit is defined as the amount of enzyme that produces
an increase of one absorbance unit per minute.
Vascular permeability analysis. Vascular permeability in lung
was estimated using the Evans Blue method. Animals received 20
mg/kg of Evans Blue by cava vein injection 15 min before sacrifice.
Lung samples were added to 10 volumes of deionized formamide and
incubated at room temperature for 24 hr and the Evans Blue ex-
tracted from tissue was quantitated by spectrophotometric analysis
and compared to results with standards of known concentrations
(22).
Protein measurement. Total protein concentration in liver homog-
enates was determined using a commercial kit from Bio-Rad (Mu-
nich, Germany).
FIGURE 1. Hepatic xanthine levels
(A) and XDH/XOD activity (B) after
ischemia and plasma xanthine (C)
and XDH/XOD activity (D) immedi-
ately after hepatic reperfusion.
Cont, Control; I, 90 min of isch-
emia; PCI, I with previous pre-
conditioning induced by 10 min of
ischemia and 10 min of reperfusion
before sustained ischemia. *P<0.05
vs. Cont; P<0.05 vs. I.
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Histological Study
Liver and lung samples were obtained, fixed in 10% neutral buff-
ered formalin, paraplast-embedded, cut into 5-m sections, and
stained with hematoxylin-eosin according to standard procedures.
Statistics
Data are expressed as meanSEM. Mean of different groups were
compared using a one-way analysis of variance. Student’s t test was
performed for evaluation of significant differences between groups.
Significance was determined at the 5% level (P0.05).
RESULTS
ROS Generating Systems in Liver Tissue and Plasma
As shown in Figure 1, a significant increase in xanthine
levels in liver (Fig. 1A) was observed after hepatic ischemia
(I). With regard to XDH and XOD activity in liver (Fig. 1B),
no change in total XDHXOD activity was observed. How-
ever, increased conversion of XDH to XOD occurred as a
consequence of ischemia, because this proportion increased
to 40%. Preconditioning previous to ischemia (PCI) atten-
uated both the increase in xanthine levels and the conversion
of XDH to XOD, because XOD represented only 20% of the
total enzymatic activity. As expected, an increase in xanthine
and XOD activity in plasma (Fig. 1, C and D, respectively)
has been shown at a few minutes after hepatic reperfusion.
When preconditioning was carried out, the increases in both
xanthine and XOD activity were attenuated.
ROS Antioxidant Systems in Liver
SOD and GSH represent well known enzymatic and non-
enzymatic antioxidant mechanisms (39, 40). We have evalu-
ated whether preconditioning, by acting through these anti-
oxidant mechanisms, could confer resistance against the
FIGURE 2. Hepatic SOD activity (A) and GSH (B) levels in the
following experimental groups: Cont, Control; I, 90 min of
ischemia; I/R, 90 min of ischemia followed by 90 min of reper-
fusion; PCI, I with previous preconditioning induced by 10
min of ischemia and 10 min of reperfusion before sustained
ischemia; PCI/R, I/R with previous preconditioning induced
by 10 min of ischemia and 10 min of reperfusion before sus-
tained ischemia. *P<.05 vs. Cont; P<0.05 vs. I; #P<0.05 vs.
I/R.
FIGURE 3. Hepatic MDA levels (A) and hepatic injury (B)
after reperfusion in the following experimental groups: Cont,
Control; I/R, 90 min of ischemia followed by 90 min of reper-
fusion; PCI/R, I/R with previous preconditioning; I/Rallop,
I/Rallopurinol; PCI/RXXOD, PCI/Rxanthine and
xanthine oxidase; PCI/RallopXXOD; I/RGSH,
I/Rglutathione ester. *P<0.05 vs. Cont; P<0.05 vs. I/R;
#P<0.05 vs. PCI/R.
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injury induced by the ROS generated after hepatic I/R. As
shown in Figure 2A, SOD activity levels found after ischemia
(I) were of the same order as in the control group but a
significant decrease in SOD levels was observed after hepatic
reperfusion (I/R). Preconditioning did not modify the de-
crease in SOD activity, suggesting that the differences in
ROS observed between nonpreconditioned and precondi-
tioned groups could not be explained by differences in SOD
activity. With regard to GSH (Fig. 2B), ischemia leads to a
reduction in hepatic GSH levels with respect to control group
which was not modified after hepatic reperfusion. However,
when ischemia was preceded by preconditioning, GSH levels
were similar to those of the control group. We proceeded to
evaluate whether a preconditioning period could modify by
itself the GSH contents before the sustained ischemia but no
differences in GSH levels with respect to control group were
found (data not shown); this suggests that the differences in
the GSH content found at the end of ischemia in animals
subjected or not to previous preconditioning, may result ei-
ther in differences in the synthesis or consumption of GSH
during the ischemic process.
Role of Xanthine/XOD and GSH on Postischemic ROS and
Hepatic Injury After Hepatic I/R
Hepatic I/R resulted in the generation of ROS, as shown by
MDA levels significantly higher than those found in the
control group (Fig. 3A). These increases in postischemic MDA
levels were prevented when preconditioning was carried out
(PCI/R). We investigated whether preconditioning by block-
ing the xanthine/XOD system during prolonged ischemia
could confer protection against hepatic injury. The inhibition
of XOD with allopurinol prevented the ROS generation (I/
Rallop). The administration of xanthine and XOD to
preconditioning group (PCI/RXXOD) resulted in MDA
levels similar to those found after hepatic reperfusion,
whereas the inhibition of XOD in this group (PCI/
RallopXXOD) prevented the effects, resulting in levels
like those found by preconditioning (see Fig. 3A). An identical
pattern was observed for hepatic injury (AST, ALT), as illus-
trated in Figure 3B. We evaluated whether the maintenance
of GSH content after hepatic ischemia induced by precondi-
tioning could contribute to attenuate the injuring effects of
ROS in I/R processes. The administration of GSH ester to I/R
(I/RGSH) resulted in MDA and transaminase levels signif-
icantly lower than those obtained after hepatic reperfusion.
Role of Circulating Xanthine/XOD on Lung Injury After
Hepatic I/R
As shown in Figure 4, either preconditioning or the inhi-
bition of XOD with allopurinol attenuated the increases in
MPO (Fig. 4A), MDA (Fig. 4B), and vascular permeability
(Fig. 4C) observed after hepatic I/R. The administration of
xanthine and XOD (PCI/RXXOD) abolished the benefits
of preconditioning, leading to MPO, MDA, and vascular
permeability values similar to those found after hepatic
I/R. In contrast, the administration of allopurinol (PCI/
RallopXXOD) abolished the adverse effects of
xanthine/XOD.
Histological Study of the Liver and Lung after Hepatic I/R
Histological changes in both liver and lung after hepatic
I/R were in keeping with the biochemical study (Figs. 5 and
FIGURE 4. MPO (A), MDA (B), and vascular permeability (C)
in lung after hepatic I/R. Cont, Control; I/R, 90 min of isch-
emia followed by 90 min of reperfusion; PCI/R, 90 min of
ischemia followed by 90 min of reperfusion with previous
preconditioning induced by 10 min of ischemia and 10 min
of reperfusion before sustained ischemia; I/Rallop,
I/Rallopurinol; PCI/RXXOD, PCI/Rxanthine and
xanthine oxidase; PCI/RallopXXOD. *P<0.05 vs. Cont;
P<0.05 vs. I/R; #P<0.05 vs. PCI/R.
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6). The histological study of the liver in the I/R (Fig. 5A) and
PCI/RXXOD (Fig. 5D) groups revealed multiple and
extensive areas of hepatocyte necrosis randomly distributed
through the hepatic parenchyma. In contrast, no hepatic
lesions or minimal lesions were observed in PCI/R (Fig. 5B)
and I/Rallop (Fig. 5C). In lung, the I/R (Fig. 6A) and PCI/
RXXOD (Fig. 6D) showed a moderate thickening of the
alveolar walls with neutrophil infiltration. By contrast, no
pulmonary lesions or minimal lesions were seen in PCI/R
(Fig. 6B) and I/Rallop (Fig. 6C).
DISCUSSION
The destructive effects of I/R arise from the acute genera-
tion of ROS subsequent to reoxygenation, which inflict direct
tissue damage and initiate a cascade of deleterious cellular
responses leading to inflammation, cell death, and organ
failure (41, 42). It has been suggested that one of the main
sources of ROS during the I/R process lies in the activity of
XOD (5). According to the model proposed by Granger et al.
(43), XDH is converted to XOD when liver tissue is subjected
to ischemia (Fig. 1). The accumulation of xanthine found
after hepatic ischemia could thus be deleterious in hepatic
I/R through the enhanced generation of ROS by the newly
formed XOD. Inhibition of XOD with allopurinol (I/Rallop)
attenuates the production of ROS, reducing also the hepatic
I/R injury. The results of the present study indicate that
preconditioning limited the accumulation of xanthine and
reduced the conversion of XDH to XOD during prolonged
ischemia. However, the administration of xanthine and XOD
to the preconditioned group (PCI/RXXOD) abolished
the benefits of preconditioning on oxidative stress and he-
patic injury. MDA, transaminase levels, and histological re-
sults similar to those found after hepatic I/R were found
(Figs. 3 and 5). Taking into in account these results, xanthine
should abolish the protection conferred by preconditioning
due to the higher levels of ROS generated by XOD. Thus, we
inhibited XOD in the preconditioned group pretreated with
XXOD to determine if this brings back the preconditioning
protection. As shown in Figure 3, the injurious effects of
xanthineXOD were prevented with previous inhibition of
XOD (PCI/RallopXXOD), resulting in MDA and
transaminase values similar to those obtained by precondi-
tioning. This data indicate that preconditioning could reduce
the postischemic ROS production by blocking xanthine/XOD,
conferring thus protection against hepatic I/R injury. Con-
versely, the deleterious effects of xanthine could also be the
result of preventing nitric oxide production by its antagonism
of the adenosine receptor. This possibility cannot be dis-
counted, because it has been reported that xanthine is also
an inhibitor of adenosine receptors (24), and the protective
role of adenosine receptor activation on hepatic I/R injury is
FIGURE 5. Histological lesions in liver after hepatic I/R. (A) I/R: focal areas of hepatocyte necrosis; (B) PCI/R: no hepatic
lesions; (C) I/Rallop: no hepatic lesions; (D) PCI/RXXOD: focal areas of hepatocyte necrosis and disruption of hepatic
architecture (*) (hematoxylin and eosin stain; magnification 255).
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well known (25–27). In our previous work, in the same ex-
perimental model used in the present study, we demon-
strated that preconditioning induces the activation of aden-
osine A2 receptors, which by eliciting an increase in nitric
oxide generation before sustained ischemia, protect against
the hepatic injury observed at 90 min of hepatic reperfusion
(25). This endogenous production of nitric oxide could confer
protection by modulating mechanisms involved in hepatic I/R
injury, including sustained hepatic vasoconstriction, which
compromises long-term recovery from hepatic I/R injury (44).
Nitric oxide is also involved in the protection conferred by
preconditioning on I/R injury associated with liver transplan-
tation (45). In addition, adenosine receptor agonists increase
nitric oxide production, and this confers a protective PC-like
effect (14, 25, 27). This effect has been reported by other
investigators in the liver (26), who go one step further and
demonstrate that adenosine receptor antagonists oppose this
effect.
Because GSH is involved in both chemical and enzymatic
cellular antioxidant defense mechanisms, a decrease in this
metabolite during prolonged ischemia (Fig. 2) is consistent
with a decline in the ability of cells to attenuate damage by
ROS. As shown in Figure 3, administration of GSH resulted
in ROS and transaminase levels significantly lower than
those obtained after hepatic I/R. Conversely, the mainte-
nance of GSH induced by preconditioning after prolonged
ischemia could also contribute to the protection against he-
patic injury.
Experimental evidence indicates that hepatic I/R is asso-
ciated with the release of XOD and xanthine from the liver
into the circulation. Then, the resulting XOD-derived oxi-
dants may act as mediators of the inflammatory response in
the lung (5, 9, 10). Neutrophils have been demonstrated to
accumulate in the lung after hepatic I/R. Activated neutro-
phils can produce oxidants and result in acute lung injury,
including increased alveolar-capillary membrane permeabil-
ity (9, 10, 23). The inhibition of XOD with allopurinol pre-
vented the neutrophil accumulation, oxidative stress, and
microvascular disorders seen in lung after hepatic I/R (Figs.
4 and 6). Values of MPO, MDA, and microvascular perme-
ability of the same order as found in control groups were
obtained. All of these data suggest that XOD may play a
pivotal role in remote tissue damage. This contention is con-
sistent with the observation that circulating xanthine and
XOD is increased in patients with adult respiratory distress
syndrome (ARDS) associated with human liver transplanta-
tion and that ARDS patients have circulating neutrophils
that are activated and sequestered in the lungs (9, 10). Pre-
conditioning reduced levels of circulating xanthine and XOD
(Fig. 1). This could confer protection against the pulmonary
FIGURE 6. Histological lesions in lung after hepatic I/R. (A) I/R: Moderate thickening of the alveolar walls with neutrophil
infiltration; (B) PCI/R: no apparent pulmonary lesions; (C) I/Rallop: no apparent pulmonary lesions; (D) PCI/RXXOD:
moderate thickening of the alveolar walls with neutrophil infiltration and perivascular neutrophil extravasation (arrows) (H & E
stain; magnification 128).
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damage after hepatic I/R. As shown in Figure 4, the admin-
istration of xanthine and XOD to the preconditioned group
(PCI/RXXOD) abolished the beneficial effects of precon-
ditioning, leading to neutrophil accumulation, values of oxi-
dative stress, and microvascular disorders similar to those
found after hepatic I/R. Histological changes in lung were in
keeping with the biochemical study (Fig. 6). PCI/
RXXOD group (Fig. 6D) showed a moderate thickening of
the alveolar walls with neutrophil infiltration, whereas no
lesions were observed in lung tissue of the PCI/R group
(Fig. 6B). The deleterious effects of xanthine may be due to
ROS generation from XOD, because the previous inhibition of
XOD with allopurinol (PCI/RallopXXOD) did not mod-
ify the benefits of preconditioning.
The results of the present study give support to the idea
that preconditioning could protect against both the hepatic
and the lung injury associated with hepatic I/R by modulat-
ing the mechanisms implicated in the local and systemic
inflammatory response. Recently, we reported that precondi-
tioning reduced the postischemic hepatic and plasma tumor
necrosis factor (TNF) release from Kupffer cells (22). How-
ever, the reduction in TNF release was important in the
protection conferred by preconditioning in lung injury, but
this would not completely explain the protection conferred by
preconditioning in liver (23). It is known that hepatic I/R
injury is a result of the multiple interactions between differ-
ent mechanisms (2, 44). The results of the present study
seem to indicate that the effect of preconditioning on xan-
thine/XOD could also contribute to attenuate both the liver
and lung injury after hepatic I/R.
In liver transplantation, the preservation-reperfusion in-
juries are still one of the most serious insults that affect
postoperative graft viability and ultimate postsurgical re-
sults (1, 2). The amount of xanthine and XOD as well as the
loss of GSH during organ preservation seem to be responsible
for ROS generation and organ damage after liver transplan-
tation (5, 8). To date, in clinical practice, addition of XOD
inhibitors, such as allopurinol or antioxidants such as GSH
in the preservation solution, is not enough to eliminate the
deleterious effects of ROS generated later during reperfusion
(5, 46). The present experimental study suggests that the
benefits of organ preconditioning could be of clinical interest,
because this surgical approach prevents the formation of
factors responsible for ROS production. Of course, intensive
investigations are necessary to evaluate if these results ob-
tained in normothermic conditions at 90 min of ischemia and
reperfusion periods could be extrapolated to long term I/R
conditions as well as to the cold ischemia conditions associ-
ated with liver transplantation. If this were possible, precon-
ditioning, by reducing xanthine accumulation and conversion
of XDH to XOD as well as by suppressing the loss of gluta-
thione during organ preservation, could prevent ROS produc-
tion, thus protecting liver grafts from subsequent I/R inju-
ries. In addition, preconditioning by modulating the levels of
circulating xanthine and XOD could attenuate the systemic
effects of hepatic I/R, such as neutrophil infiltration, oxidant
stress, and microvascular disorders into the lung.
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